SAMSN1 and neoplasm: At 7 weeks post‐tumor cell inoculation, 5 of the 20 (25%) C57BL/Samsn1−/− mice injected with EV control 5TGM1 cells had developed tumor, whereas none of the 21 (0%) C57BL/6/Samsn1−/− mice that were injected with 5TGM1‐Samsn1 cells had any evidence of disease development, as determined by BLI and SPEP (Figure 8D‐F).